• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

New Delhi, Aug. 22

Dabur Pharma has received the US Food and Drug Administration’s approval for the Abbreviated New Drug Application (ANDA) for the chemotherapy injection, Epirubicin. The injection, a generic version of Pfizer’s Ellence, is used in the early treatment of breast cancer, said the company in a statement.

According to Dabur Pharma, the drug has an annual sale of about $ 60 million. The company will sell 50 mg and 200 mg dosages in the US. “We are pleased to announce our third USFDA approval in the last one year. This bears testimony to the strong foundation that we are laying towards becoming one of the leading oncology players across the globe,” said Mr Ajay K Vij, CEO, Dabur Pharma. Dabur Pharma claims to be India’s largest player in the Oncology segment, with a market cap of over Rs 1,000 crore. —

Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ranbaxy launches urology drug

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line